Sana Biotechnology Inc (SANA)
10.44
+0.66
(+6.75%)
USD |
NASDAQ |
May 03, 16:00
10.44
0.00 (0.00%)
After-Hours: 20:00
Sana Biotechnology SG&A Expense (Quarterly): 20.78M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 20.78M |
September 30, 2023 | 19.18M |
June 30, 2023 | 16.57M |
March 31, 2023 | 16.77M |
December 31, 2022 | 23.32M |
September 30, 2022 | 15.51M |
June 30, 2022 | 18.29M |
March 31, 2022 | 14.43M |
December 31, 2021 | 12.68M |
Date | Value |
---|---|
September 30, 2021 | 13.43M |
June 30, 2021 | 12.48M |
March 31, 2021 | 11.82M |
December 31, 2020 | 9.207M |
September 30, 2020 | 7.099M |
June 30, 2020 | 6.009M |
March 31, 2020 | 5.955M |
December 31, 2019 | 5.818M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
5.818M
Minimum
Dec 2019
23.32M
Maximum
Dec 2022
13.49M
Average
13.43M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Rocket Pharmaceuticals Inc | 21.54M |
Solid Biosciences Inc | 6.812M |
Dyne Therapeutics Inc | 24.62M |
Taysha Gene Therapies Inc | 6.719M |
Tenaya Therapeutics Inc | 8.581M |